| Rank |
Pathway / Axis |
Cancer Cells (↑/↓/↔ + qualifiers) |
Normal Cells (↑/↓/↔ + qualifiers) |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
ROS / Redox buffering |
↓ ROS (often primary; context-dependent) |
↓ ROS (protective; often primary) |
P–R |
Antioxidant/ROS quenching |
Can blunt ROS-mediated cytotoxic therapies; shown to reduce radiation-induced ROS/apoptosis in HCC models with ~10 µM pretreatment used in vitro (high vs typical plasma ~1–1.5 µM after coffee). :contentReference[oaicite:2]{index=2} |
| 2 |
Keap1 → NRF2 (ARE program) |
↑ NRF2 signaling (can promote resistance) |
↑ NRF2 signaling (tissue protection) |
R–G |
Cytoprotective gene induction |
In HCC, NRF2 induction/nuclear translocation linked to radioresistance; NRF2 knockdown reversed CGA-mediated protection. NRF2 hyperactivity is a known radio/chemo-resistance axis in cancers. :contentReference[oaicite:3]{index=3} |
| 3 |
Radiotherapy interaction (ROS-dependent killing) |
↑ radioresistance (model-dependent; NRF2/ROS) |
↔ to ↑ protection of normal tissues |
P–R |
Therapy antagonism risk |
Evidence CGA can hinder RT efficacy in some tumor models via ROS scavenging + NRF2 activation. :contentReference[oaicite:4]{index=4} |
| 4 |
Inflammation: NF-κB-related signaling |
↓ pro-inflammatory signaling (context-dependent) |
↓ pro-inflammatory signaling (protective) |
R–G |
Anti-inflammatory modulation |
Commonly reported across CGA-family reviews; may reduce tumor-promoting inflammation but can also reduce immunogenic stress signals depending on context. :contentReference[oaicite:5]{index=5} |
| 5 |
PI3K/Akt/mTOR & metabolic stress axes |
↓ PI3K/Akt/mTOR (model-/dose-dependent; often high concentration) |
↔ / context-dependent |
R–G |
Anti-proliferative signaling (preclinical) |
Frequently claimed in preclinical systems; translational relevance depends on achievable tissue levels and tumor genotype. :contentReference[oaicite:6]{index=6} |
| 6 |
Apoptosis / Autophagy balance |
↑ apoptosis or ↑ autophagy (model-dependent; often high concentration) |
↓ apoptosis under toxic stress (protective) |
R–G |
Programmed cell-death tuning |
Dual-use phenotype: “anticancer” apoptosis claims vs “chemoprotection” in normal tissues. Net effect depends on baseline stress + co-therapy. :contentReference[oaicite:7]{index=7} |
| 7 |
Chemo-sensitization vs chemo-protection (adjuvant role) |
↔ / mixed (chemo-sensitizing in some models; resistance risk via NRF2 in others) |
↑ protection from chemo-toxicity (oxidative/inflammatory injury) |
R–G |
Adjunct (preclinical) |
2024 review frames CGA as potential adjuvant for both overcoming resistance and reducing toxicity, but direction varies by drug/model and redox state. :contentReference[oaicite:8]{index=8} |
| 8 |
Ca²⁺ signaling |
↔ (not consistently primary) |
↔ (not consistently primary) |
— |
Usually secondary |
Ca²⁺ is not a canonical primary axis for CGA in most cancer summaries; include if a specific model ties CGA to ER/mitochondrial Ca²⁺ stress. |
| 9 |
Ferroptosis |
↔ / context-dependent |
↔ / context-dependent |
— |
Usually secondary |
CGA’s dominant profile is antioxidant/NRF2; that generally counters lipid-peroxidation–driven ferroptosis unless paired with pro-oxidant triggers. |
| 10 |
Clinical Translation Constraint |
Systemic tumor exposure likely low; many in-vitro effects require ≥10 µM |
— |
PK / context risk |
Human coffee dosing yields median peak plasma ~1.1–1.5 µM (metabolites); high in-vitro dosing + NRF2-mediated therapy antagonism are key constraints. :contentReference[oaicite:9]{index=9} |